Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Cambridge Cognition Holdings Plc
Directorate Change
Published Oct 18 2024
3 min read

Directorate Change

Homepage - Cambridge Cognition

 

18 October 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Directorate change

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that, further to the announcement made on 12 September 2024 in which it stated that Dr Matthew Stork had stepped down as Chief Executive Officer, the Company has now received the formal resignation of Dr Stork as a Director of the Company and all subsidiary entities of which he was a Director. 

 

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Dr Steven Powell, Chairman

c/o Hudson Sandler 

Panmure Liberum Limited (NOMAD and Joint Broker) 

Freddy Crossley / Will Goode / Mark Rogers 

Rupert Dearden 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

 

Tel: 020 3903 7715 

 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus / Harry Griffiths

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 


Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit: https://cambridgecognition.com/